Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial

Authors not listed

University of Roma La Sapienza · 2019

Abstract

Sarcopenia is an independent predictor of morbidity and mortality in the cirrhotic patient. Beta-hydroxy-beta-methyl butyrate (HMB) is a leucine metabolite with potential efficacy in increasing protein synthesis, muscle mass, and its functionality. The aim of this randomized controlled study is to evaluate the effect of nutritional supplementation with HMB and physical activity both on muscle mass and on muscle function in cirrhotic patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Anonymous. (2019). Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial. <em>University of Roma La Sapienza</em>. https://clinicaltrials.gov/study/NCT03892070
Vancouver
Anonymous. Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial. University of Roma La Sapienza. 2019.
BibTeX
@misc{anon2019BetaHy, title = {Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial}, author = {Anonymous}, journal = {University of Roma La Sapienza}, year = {2019}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings